CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 100 target
Drug / intervention
177Lu girentuximab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05663710
NCT05663710Phase 2RecruitingOn Track
Long Recruiting
CompareCT.gov

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

M.D. Anderson Cancer Center·interventional·Posted Dec 23, 2022·Updated May 5, 2026

In Brief

A Phase 2 clinical trial evaluating 177Lu girentuximab, Nivolumab, and 2 other interventions for Advanced Cancer and Clear Cell Renal Cell Carcinoma. Currently recruiting, targeting 100 participants across 1 site.

Detailed Summary

To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer, Clear Cell Renal Cell Carcinoma
CountriesUnited States
CollaboratorsTelix Pharmaceuticals (Innovations) Pty Limited, United States Department of Defense

Timeline

Phase 2Recruiting
20232024202520262027
First PostedDec 23, 2022
Enrollment StartJun 30, 2023
Primary CompletionOct 30, 2027
TodayJul 1, 2026
Enrollment to primary: 4.3 yearsPosted 3.5 years agoPrimary completion in 1.3 years

Interventions

177Lu girentuximabdrug

Given by IV (vein)

Nivolumabdrug

Given by IV (vein)

Cabozantinibdrug

Given by PO

ArabinoFuranosylGuanine [18F]F-AraGdrug

Given by IV (vein)